News|Articles|December 27, 2025

Top 5 news articles of 2025

Author(s)MHE Staff
Listen
0:00 / 0:00

Key Takeaways

  • A Drexel University researcher finds insufficient evidence connecting acetaminophen use during pregnancy to neurodevelopmental disorders.
  • Medicare's negotiated drug prices, starting January 2026, offer modest discounts but may have unintended consequences for beneficiaries.
SHOW MORE

Tylenol and autism, the Inflation Reduction Act, the One Big Beautiful Bill, Most Favored Nation pricing and direct drug sales to consumers were some of the biggest news items we covered in 2025.

Researcher on Tylenol-autism connection: Not the best science

Drexel University Dornsife School of Public Health researcher discusses the lack of evidence to support a link between acetaminophen use during pregnancy and neurodevelopmental disorders.

Read more

What IRA drug prices will mean for PBMs, health plans and patients

Medicare's first negotiated drug prices, effective January 2026, provide modest discounts, with limited savings for most beneficiaries and some unintended consequences.

Read more

Orphan drug loophole shields blockbuster drugs from price negotiations

A provision in the One Big Beautiful Bill delays or exempts high-spending medications with orphan indications from Medicare drug price negotiations.

Read more

Trump’s favored nation drug pricing is unworkable, critics say

Industry leaders and policy experts have said President Trump’s executive order on Most Favored Drug Pricing is flawed and ignores the basic economics of the global drug marketplace.

Read more

Selling direct

Drugmakers are scrambling to set up direct-to-consumer programs in response to President Donald Trump’s executive orders. Should pharmacy benefit managers be worried? Are the programs good for patients?

Read more

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.


Latest CME